Tumour necrosis factor alpha mRNA expression in early multiple sclerosis lesions: Correlation with demyelinating activity and oligodendrocyte pathology

Citation
A. Bitsch et al., Tumour necrosis factor alpha mRNA expression in early multiple sclerosis lesions: Correlation with demyelinating activity and oligodendrocyte pathology, GLIA, 29(4), 2000, pp. 366-375
Citations number
55
Categorie Soggetti
Neurosciences & Behavoir
Journal title
GLIA
ISSN journal
08941491 → ACNP
Volume
29
Issue
4
Year of publication
2000
Pages
366 - 375
Database
ISI
SICI code
0894-1491(20000215)29:4<366:TNFAME>2.0.ZU;2-4
Abstract
The precise role of tumour necrosis factor alpha (TNF alpha) in multiple sc lerosis (MS) is still controversial. Most findings from the animal model ex perimental allergic encephalomyelitis have yet to be confirmed in multiple sclerosis. The aim of this study was to define the significance of TNF alph a with respect to the hallmark of MS, that is demyelination. Therefore, 78 lesion areas from diagnostic brain biopsies of 32 patients were analysed. L esion demyelinating activity was classified by the presence of myelin degra dation products in macrophages and macrophage activation markers. Nonradioa ctive in situ hybridisation tvas carried out to detect TNF alpha mRNA expre ssing cells. DNA fragmentation was visualised by TdT-mediated X-dUTP nick e nd labeling. A significantly higher number of cells expressed TNF alpha mRN A in active demyelinating lesions than in inactive or remyelinating lesions irrespective of the extent of the inflammatory infiltrate. TNF alpha mRNA expression correlated with the appearance of DNA fragmentation in T lymphoc ytes and oligodendrocytes within the lesions. In the periplaque white matte r, expression of TNF alpha mRNA negatively correlated with oligodendrocyte numbers. These data support previous findings from animal models and in vit ro experiments. Although not proving, the current study strongly suggests a pathogenic role of TNF alpha in demyelination in human multiple sclerosis and gives further support for TNF alpha-directed therapeutic strategies. (C ) 2000 Wiley-Liss, Inc.